Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,125JPY
12 Dec 2017
Change (% chg)

¥-55 (-0.89%)
Prev Close
¥6,180
Open
¥6,150
Day's High
¥6,152
Day's Low
¥6,113
Volume
1,828,200
Avg. Vol
1,985,441
52-wk High
¥6,464
52-wk Low
¥4,664

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.74
Market Cap(Mil.): ¥4,887,839.00
Shares Outstanding(Mil.): 790.91
Dividend: 90.00
Yield (%): 2.91

Financials

  Industry Sector
P/E (TTM): -- 31.83 15.71
EPS (TTM): -- -- --
ROI: -- 15.03 31.93
ROE: -- 16.54 16.16

Amgen's Kyprolis improves overall survival in blood cancer patients

Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Dec 11 2017

UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Dec 11 2017

BRIEF-Takeda Pharma Announces Research Collaboration In ALS With Montreal Neurological Institute​

* TAKEDA PHARMACEUTICAL ANNOUNCES RESEARCH COLLABORATION IN ALS WITH MONTREAL NEUROLOGICAL INSTITUTE​

Dec 04 2017

BRIEF-Takeda Pharmaceutical unit signs agreement for sale of properties worth 49.5 bln yen

* Says its wholly owned subsidiary Takeda Pharmaceutical Real Estate Company has signed an agreement with Takashimaya Company Limited for the sale of properties

Dec 01 2017

Ariad Pharmaceuticals settles investor lawsuit for $3.5 million

Ariad Pharmaceuticals Inc has agreed to pay $3.5 million to resolve a proposed class action claiming the drugmaker misled investors about safety issues related to a leukemia drug it was developing.

Nov 30 2017

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol

Nov 15 2017

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

Nov 14 2017

Takeda takes on Sanofi with new global dengue vaccine data

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Nov 06 2017

Takeda takes on Sanofi with new global dengue vaccine data

Nov 7 Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Nov 06 2017

BRIEF-Takeda and HemoShear Therapeutics enter drug discovery partnership in liver diseases

* Takeda and HemoShear Therapeutics enter into exclusive drug discovery partnership in liver diseases

Oct 17 2017

Earnings vs. Estimates